The FDA issued separate early approvals for Denali’s Avlayah and Corcept Therapeutics’ Lifyorli, reinforcing momentum for programs that can win accelerated or shortened review timelines. Corcept’s relacorilant was cleared for platinum-resistant ovarian cancer in combination with nab-paclitaxel nearly four months ahead of its PDUFA date. Denali’s Hunter syndrome approval similarly came ahead of April’s target date, after a sequence of setbacks for rare-disease developers. In parallel, reporting noted a broader FDA emphasis on evidence thresholds and manufacturing reliability as the agency tightens its rare-disease stance. Together, the approvals sharpen the industry focus on how endpoint strategy and delivery platform credibility are being translated into regulatory outcomes—especially for therapies seeking to address unmet need in challenging therapeutic areas.